DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for orchitis — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOrchitis maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for orchitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
androgen receptor (AR) — AR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1r,2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5CJ6 · 2.07 Å · ligand 2-chloro-4-{[(1R,2R)-2-hydroxy-2-methylcyclopentyl]amino}-3-methylbenzonitrile (51Y). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1956 · 12 citations
EFFECT OF CORTISONE IN ORCHITIS OF EPIDEMIC PAROTITIS (MUMPS)
Abstract• Epididymo-orchitis occurs in about 18 to 35% of cases of mumps. Orally given cortisone was used to treat five patients with this orchitis; 300 mg. was administered for the first day, then at least 100 mg. a day for three days or more was used for maintenance, followed by the usual gradual withdrawal period. Significant symptomatic relief, evidenced by less pain and tenderness, occurred within 24 hours, but the duration of the infection and febrile response was apparently not shortened on the initially affected side. The subsequent contralateral orchitis, which occurred in three of the five cases, did appear milder and of shorter duration.
American Journal of Clinical Pathology · 1960 · 9 citations
Granulomatous Orchitis
AbstractJournal Article Granulomatous Orchitis Get access T. H. Capers T. H. Capers Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 34, Issue 2, 1 August 1960, Pages 139–145, https://doi.org/10.1093/ajcp/34.2.139 Published: 01 August 1960 Article history Received: 16 January 1960 Revision received: 01 April 1960 Accepted: 13 April 1960 Published: 01 August 1960
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
